Chang-Zhu He, Zhao-Jun Zeng, Jun Qiao Liu, Qin Qiu, Yu He
{"title":"治疗干眼症患者的自体血清滴眼液:随机对照试验的系统回顾和荟萃分析","authors":"Chang-Zhu He, Zhao-Jun Zeng, Jun Qiao Liu, Qin Qiu, Yu He","doi":"10.3389/fmed.2024.1430785","DOIUrl":null,"url":null,"abstract":"BackgroundDry eye disease (DED) is highly prevalent worldwide, leading to increased medical costs, economic burdens on families and society, and a diminished quality of life for patients. The utilization of autologous serum eye drops (ASEDs) for the treatment of DED is progressively rising.ObjectiveTo further evaluate the efficacy and safety of ASEDs in the treatment of DED.MethodsA thorough search for randomized controlled trials (RCTs) was conducted across eight databases, including PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, SinoMed, and VIP. This search encompassed the inception of each database up to April 1, 2024, with a specific focus on identifying RCTs evaluating the efficacy and safety of ASEDs for the treatment of DED. Data analysis was conducted utilizing Stata 15.0 software and the Cochrane Risk of Bias Assessment Tool was utilized to appraise the literature’s quality.ResultsThe study encompassed 12 RCTs. In comparison to the use of artificial tears (AT), patients diagnosed with DED who utilized ASEDs displayed elevated the Schirmer test (ST) scores [WMD = 2.35, 95% CI (1.45, 3.24), <jats:italic>p</jats:italic> &lt; 0.001] and tear-film breakup time (TBUT) scores [WMD = 2.83, 95% CI (2.27, 3.39), <jats:italic>p</jats:italic> &lt; 0.001], decreased Corneal fluorescence staining (CFS) scores [SMD = −2.11, 95% CI (−3.07, −1.15), <jats:italic>p</jats:italic> &lt; 0.001] and the Ocular Surface Disease Index (OSDI) scores [WMD = −10.54, 95% CI (−13.31, −7.77), p &lt; 0.001], and experienced a reduced frequency of adverse events [RR = 0.36, 95% CI (0.13, 0.99), <jats:italic>p</jats:italic> = 0.048].ConclusionIn this study, ASEDs had been shown to enhance tear secretion, extend tear film break-up time, mitigate corneal epithelial damage, ameliorate OSDI scores, and exhibit greater safety compared to AT.","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Autologous serum eye drops for patients with dry eye disease: a systematic review and meta-analysis of randomized controlled trials\",\"authors\":\"Chang-Zhu He, Zhao-Jun Zeng, Jun Qiao Liu, Qin Qiu, Yu He\",\"doi\":\"10.3389/fmed.2024.1430785\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BackgroundDry eye disease (DED) is highly prevalent worldwide, leading to increased medical costs, economic burdens on families and society, and a diminished quality of life for patients. The utilization of autologous serum eye drops (ASEDs) for the treatment of DED is progressively rising.ObjectiveTo further evaluate the efficacy and safety of ASEDs in the treatment of DED.MethodsA thorough search for randomized controlled trials (RCTs) was conducted across eight databases, including PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, SinoMed, and VIP. This search encompassed the inception of each database up to April 1, 2024, with a specific focus on identifying RCTs evaluating the efficacy and safety of ASEDs for the treatment of DED. Data analysis was conducted utilizing Stata 15.0 software and the Cochrane Risk of Bias Assessment Tool was utilized to appraise the literature’s quality.ResultsThe study encompassed 12 RCTs. In comparison to the use of artificial tears (AT), patients diagnosed with DED who utilized ASEDs displayed elevated the Schirmer test (ST) scores [WMD = 2.35, 95% CI (1.45, 3.24), <jats:italic>p</jats:italic> &lt; 0.001] and tear-film breakup time (TBUT) scores [WMD = 2.83, 95% CI (2.27, 3.39), <jats:italic>p</jats:italic> &lt; 0.001], decreased Corneal fluorescence staining (CFS) scores [SMD = −2.11, 95% CI (−3.07, −1.15), <jats:italic>p</jats:italic> &lt; 0.001] and the Ocular Surface Disease Index (OSDI) scores [WMD = −10.54, 95% CI (−13.31, −7.77), p &lt; 0.001], and experienced a reduced frequency of adverse events [RR = 0.36, 95% CI (0.13, 0.99), <jats:italic>p</jats:italic> = 0.048].ConclusionIn this study, ASEDs had been shown to enhance tear secretion, extend tear film break-up time, mitigate corneal epithelial damage, ameliorate OSDI scores, and exhibit greater safety compared to AT.\",\"PeriodicalId\":12488,\"journal\":{\"name\":\"Frontiers in Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fmed.2024.1430785\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2024.1430785","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景干眼症(DED)在全球范围内发病率很高,导致医疗费用增加、家庭和社会经济负担加重以及患者生活质量下降。方法 在 PubMed、EMBASE、Cochrane Library、Web of Science、China National Knowledge Infrastructure、Wanfang、SinoMed 和 VIP 等八个数据库中对随机对照试验(RCT)进行了全面检索。该检索涵盖了从每个数据库建立之初到 2024 年 4 月 1 日的所有时间,重点是确定评估 ASED 治疗 DED 的有效性和安全性的 RCT。研究使用Stata 15.0软件进行数据分析,并使用Cochrane偏倚风险评估工具对文献质量进行评估。与使用人工泪液(AT)相比,使用 ASEDs 的 DED 患者的施尔默试验(ST)评分升高 [WMD = 2.35, 95% CI (1.45, 3.24), p &;lt; 0.001]和泪膜破裂时间(TBUT)评分[WMD = 2.83, 95% CI (2.27, 3.39), p < 0.001],角膜荧光染色(CFS)评分降低[SMD = -2.11, 95% CI (-3.07, -1.15), p < 0.001]和眼表疾病指数(OSDI)评分[WMD = -10.54,95% CI (-13.31, -7.77),p&;lt; 0.001],不良事件发生频率降低[RR = 0.36,95% CI (0.13, 0.99),p = 0.048].结论在这项研究中,ASEDs 被证明能促进泪液分泌,延长泪膜破裂时间,减轻角膜上皮损伤,改善 OSDI 评分,并且与 AT 相比具有更高的安全性。
Autologous serum eye drops for patients with dry eye disease: a systematic review and meta-analysis of randomized controlled trials
BackgroundDry eye disease (DED) is highly prevalent worldwide, leading to increased medical costs, economic burdens on families and society, and a diminished quality of life for patients. The utilization of autologous serum eye drops (ASEDs) for the treatment of DED is progressively rising.ObjectiveTo further evaluate the efficacy and safety of ASEDs in the treatment of DED.MethodsA thorough search for randomized controlled trials (RCTs) was conducted across eight databases, including PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, SinoMed, and VIP. This search encompassed the inception of each database up to April 1, 2024, with a specific focus on identifying RCTs evaluating the efficacy and safety of ASEDs for the treatment of DED. Data analysis was conducted utilizing Stata 15.0 software and the Cochrane Risk of Bias Assessment Tool was utilized to appraise the literature’s quality.ResultsThe study encompassed 12 RCTs. In comparison to the use of artificial tears (AT), patients diagnosed with DED who utilized ASEDs displayed elevated the Schirmer test (ST) scores [WMD = 2.35, 95% CI (1.45, 3.24), p < 0.001] and tear-film breakup time (TBUT) scores [WMD = 2.83, 95% CI (2.27, 3.39), p < 0.001], decreased Corneal fluorescence staining (CFS) scores [SMD = −2.11, 95% CI (−3.07, −1.15), p < 0.001] and the Ocular Surface Disease Index (OSDI) scores [WMD = −10.54, 95% CI (−13.31, −7.77), p < 0.001], and experienced a reduced frequency of adverse events [RR = 0.36, 95% CI (0.13, 0.99), p = 0.048].ConclusionIn this study, ASEDs had been shown to enhance tear secretion, extend tear film break-up time, mitigate corneal epithelial damage, ameliorate OSDI scores, and exhibit greater safety compared to AT.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world